BUSINESS
Dr Reddy's targets new launches, potential M&A as gRevlimid tapers off in America
Dr Reddy's CFO Narasimham recently told to Moneycontrol he is confident of 'sustained double-digit sales growth' in FY26, with EBITDA and Return on Capital Employed (ROCE) at 25% or above. Some analysts are circumspect about the ability to fully offset the 'gRevlimid void' in the medium term.
BUSINESS
In Sickness & In Health: Lilly, Apollo Hospitals join forces to tackle obesity, diabetes
The collaboration will span over 200 Apollo clinics and involve 300 medical practitioners, focusing on patient education, healthcare provider training, and infrastructure development.
BUSINESS
Alkem Laboratories net profit rises 4.2% to ₹305.9 crore in Q4FY25
BUSINESS
IKS Health CEO sees growth surge for tech services as US govt drives down healthcare spends
The total TAM (total addressable market) is about $225 billion, of which only $34 billion has been outsourced, Gupta said in a recent interview
BUSINESS
Novo Nordisk to launch blockbuster obesity drug Wegovy in India soon
"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide for comprehensive weight management and obesity treatment," the company told Moneycontrol in an email statement.
BUSINESS
Akums Q4 net profit drops 4.3% despite revenue growth
For the full year FY25, total income rose 1% YoY to ₹4,170 crore, adjusted EBITDA was flat at ₹513 crore and margin rose slightly to 12.3%.
BUSINESS
India sees uptick in COVID cases. What are the symptoms, should you be worried?
Two new Omicron sub-variants, LF.7 and NB.1.8, are behind the rise in cases, which have crossed the 1,000 mark
BUSINESS
Glenmark Q4 net profit rises 11% on strong Europe sales
“Our performance reflects the underlying resilience of our business and the strength of our diversified portfolio,” said Glenn Saldanha, Chairman & MD. “We are committed to building on this momentum in FY26, with a sharper focus on innovation and global scale.”
BUSINESS
Sun Pharma sees mid-to-high single-digit growth in FY26, bets big on specialty expansion
The company also expects R&D spending to rise to 6–8% of sales, reflecting its commitment to pipeline expansion and innovation.
BUSINESS
Strides Pharma Q4 net profit surges 5x on strong US sales
Strides also reduced its net debt by Rs 512.8 crore, bringing the net debt-to-EBITDA ratio down to 1.9x. The board recommended a dividend of Rs 4 per share for FY25.
BUSINESS
Emcure net profit zooms 63% to Rs 197 crore in Q4FY25
The international segment recorded a 15.6 percent year-over-year growth in sales, reaching Rs 1,187 crore. This was significantly bolstered by a robust 39.3 percent growth in the rest of the world segment.
BUSINESS
Antara Senior Care to invest Rs 500 crore to expand capacity fourfold
The company plans to ramp up its care home bed capacity to 2,000 beds and develop 10–12 new senior living communities.
BUSINESS
Mankind Pharma's Q4 net profit drops 10% to Rs 477 crore on one-off costs
The company has a net debt of Rs 5,784 crore, which translates into net debt to adjusted EBITDA ratio of 1.8x.
BUSINESS
Aster DM Healthcare Q4 net profit jumps 21% on margin gains; merger with Quality Care advances
Revenue for Q4 FY25 rose 2% YoY to Rs 1,000 crore, while operating EBITDA grew 16% to Rs 193 crore.
BUSINESS
Gland Pharma Q4 net profit slips 3% as US sales moderate; focus shifts to complex injectables, CDMO growth
“FY25 was a year of strategic realignment and investment in future growth,” said Executive Chairman Srinivas Sadu.
BUSINESS
Zydus targets FY26 expansion, but warns of slower US momentum post-Revlimid peak
The US business, a significant contributor to its revenue, is projected for single-digit growth in FY26.
BUSINESS
Max Healthcare Q4FY25 net profit rises 21% on higher patient volumes; expansion plans in focus
The company announced strategic expansion initiatives to bolster its pan-India presence including plans to add 1,500 beds in FY26 through brownfield expansions at Saket, Nanavati, and Mohali hospitals.
BUSINESS
IHH’s NTK ups damages claim against Daiichi Sankyo to Rs 11,800 crore in Fortis deal dispute
The revised claim stems from NTK’s allegations that Daiichi Sankyo obstructed its 2018 open offer to acquire shares in India’s Fortis Healthcare and its subsidiary Fortis Malar Hospitals.
COMPANIES
JB Pharma eyeing 12% growth, open to acquisitions, says CEO Nikhil Chopra
Acknowledged a subdued sentiment, Chopra is confident of JB Pharma's ability to outgrow the market ‘due to its focus on progressive categories and better execution’
BUSINESS
Nobel Hygiene raise Rs 170 crore from Neo Asset Management
The investment, a mix of primary and secondary infusion, will fuel Nobel Hygiene's growth and market expansion as the adult diaper maker eyes an initial public offering
BUSINESS
Piramal Pharma’s Nandini Piramal eyes FY30 milestone amid muted FY26 outlook
The company’s FY30 goals include $2 billion in revenue, 25 percent EBITDA margin and net debt to EBITDA below 1x, says Nandini Piramal
BUSINESS
As sleeplessness rises, India turns to melatonin supplements
While a relatively recent phenomenon, its prevalence is increasing rapidly, with 85% or respondents in a survey saying they were not getting a good night’s rest
BUSINESS
JB Pharma Q4FY25 net profit Rises 15% on domestic, CDMO strength
Net profit rose to ₹146 crore, while revenue grew 10 percent to ₹949 crore.
BUSINESS
Indian drugmakers see potential tail wind in Trump’s MFN drug pricing plan
Industry executives feel that the direct-to-government sales could open new channels, giving generic manufacturers some advantage in US market known for the steep pricing pressure.
